RxDoctor Payments Data

Rhea Sancassani, MD

Cardiovascular Disease · Miami, FLNPI 1003017112

Payments from drug & device makers

$14,908in general payments, 2019–2025

Across 123 payments — averaging $121.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$13K
  • Novartis$412
  • AstraZeneca$326
  • E.r. Squibb & Sons, L.L.C.$198
  • Johnson & Johnson$194
  • Amgen$123
  • plus $460 from 16 others

What the payments were for

  • Speaking & faculty fees$12,69085%
  • Food & beverage$2,20115%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,908 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$55,643
Medicare patients
840
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan36$45,519
FarxigaDapagliflozin Propanediol30$33,249
EliquisApixaban20$28,130
VascepaIcosapent Ethyl11$9,716
NexletolBempedoic Acid19$8,409
Ranolazine ErRanolazine17$4,305
Propafenone Hcl ErPropafenone Hcl13$1,708
Isosorbide Dinitrate27$1,073
Rosuvastatin Calcium65$896
Ezetimibe21$657
Nitroglycerin18$577
Metoprolol Succinate33$451
Losartan Potassium35$430
Carvedilol61$408
Atorvastatin Calcium41$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$412$45,51936 claims
AstraZenecaFarxiga$326$33,24930 claims
PfizerEliquis$13,195$28,13020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →